Dulaglutide

Dulaglutide

Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist engineered as a fusion protein consisting of two GLP-1 analogue sequences linked to a modified human IgG4-Fc antibody fragment. This molecular design confers an extended half-life of approximately five days, enabling once-weekly dosing in clinical study protocols and making it a pharmacokinetically distinct compound within the GLP-1 agonist class. Research into Dulaglutide has investigated its mechanism of action at GLP-1 receptors in the pancreas, brain, gastrointestinal tract, and cardiovascular tissue, examining how sustained receptor activation influences insulin secretion, glucagon suppression, gastric emptying, and central appetite regulation. Studies have explored its effects on glycaemic control and body weight reduction in metabolic disease models. Researchers have also investigated Dulaglutide’s potential cardiovascular effects, with studies examining its influence on heart rate, blood pressure, and markers of cardiovascular risk. Its Fc-fusion architecture distinguishes it structurally from other GLP-1 receptor agonists, making it a useful compound for researchers studying the pharmacokinetic and pharmacodynamic implications of Fc-fusion technology in peptide hormone biology, as well as for those investigating GLP-1 receptor biology more broadly.